Table 2.
The information of 47 studies included in the meta-analysis of CVD to fatal COVID-19
| No. | Author (year studied) | Country | Study type | Sample size (N) | Mortality rate | Age (yrs) | Non-survivors |
Survivors |
NOS score | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | CVDs | N | CVDs | ||||||||
| 1 | Abbasi, B. (2020) | Iran | A retrospective cohort study | 262 | 21.4% | 58 (43–67#) | 56 | 34 (60.7%¶) | 206 | 44 (21.4%) | 6 |
| 2 | Aladağ, N. (2020) | Turkey | A retrospective cohort study | 50 | 30.0% | 64.80 (50.3–79.3) | 15 | 7 (46.67%) | 35 | 25 (71.43%) | 6 |
| 3 | Alamdari, N. M. (2020) | Iran | A large-scale retrospective cross-sectional study | 459 | 13.7% | 61.8 (49.9–73.7) | 63 | 29 (46.0%) | 396 | 156 (39.4%) | 5 |
| 4 | Alvarez-Garcia, J. (2020) | USA | A retrospective cohort study | 6439 | 25.8% | 63.5 (45.9–81.1) | 1664 | 169 (10.2%) | 4775 | 253 (5.3%) | 8 |
| 5 | An, W. (2020) | China | A retrospective cohort study | 110 | 10.0% | – | 11 | 1 (9.1%) | 99 | 4 (4.0%) | 7 |
| 6 | Bursi, F. (2020) | Italy | A retrospective cohort study | 49 | 32.7% | 65.7 (53.1–78.3) | 16 | 6 (37.5%) | 33 | 5 (15.2%) | 7 |
| 7 | Cao, Y. (2020) | China | A two-centre retrospective case control study | 101 | 34.7% | 56.6 (41.5–71.7) | 35 | 11 (31.4%) | 66 | 10 (15.2%) | 7 |
| 8 | Carrillo-Vega, M. F. (2020) | Mexico | A descriptive cohort study | 9946 | 9.7% | 48.2 (33.8–62.5) | 963 | 64 (6.6%) | 8983 | 246 (6.3%) | 6 |
| 9 | Carter, B. (2020) | UK and Italy | A multi-centre international observational cohort study | 1559 | 27.1% | 74.0 (61.0–83.0) | 422 | 132 (31.3%) | 1137 | 213 (18.7%) | 7 |
| 10 | Chen, F. F. (2020) | China | A retrospective cohort study | 681 | 15.3% | 65.0 (54.0–72.0) | 104 | 25 (24.0%) | 577 | 55 (9.5%) | 5 |
| 11 | Chen, R. (2020) | China | A retrospective cohort study | 1590 | 3.1% | 69 (51–86) | 50 | 8 (16.0%) | 1540 | 51 (3.3%) | 5 |
| 12 | Chilimuri, S. (2020) | USA | A retrospective cohort study | 375 | 42.7% | 63.0 (52.0–72.0) | 160 | 38 (23.8%) | 215 | 24 (11.2%) | 5 |
| 13 | Ciardullo, S. (2020) | Italy | A single-centre retrospective cohort study | 373 | 38.1% | 72 (58–86) | 142 | 65 (45.8%) | 231 | 75 (32.5%) | 5 |
| 14 | Ciceri, F. (2020) | Italy | An observational cohort study | 410 | 23.2% | 65 (56–75) | 95 | 25 (26.3%) | 315 | 26 (8.3%) | 7 |
| 15 | Cipriani, A. (2020) | Italy | A single-centre observational cohort study | 109 | 18.3% | 71 (60–81) | 20 | 9 (45.0%) | 89 | 9 (10.1%) | 6 |
| 16 | Di Castelnuovo, A. (2020) | Italy | A national retrospective observational cohort study | 3762 | 17.5% | – | 665 | 165 (24.8%) | 3097 | 266 (8.6%) | 7 |
| 17 | Eslami, V. (2020) | Iran | A single-centre prospective cohort study | 87 | 14.9% | 54.6 (39.3–69.9) | 13 | 4 (30.8%) | 74 | 11 (14.9%) | 7 |
| 18 | Farré, N. (2020) | Spain | A single-centre cohort study | 623 | 11.9% | – | 74 | 15 (20.3%) | 549 | 18 (3.3%) | 7 |
| 19 | Ferrando, C. (2020) | Spain and Andorra | A multi-centre prospective observational and cohort study | 663 | 30.6% | 64 (56–72) | 203 | 6 (3.0%) | 460 | 3 (0.7%) | 7 |
| 20 | Grasselli, G. (2020) | Italy | A retrospective observational cohort study | 1715 | 53.4% | 64 (56–70) | 915 | 224 (24.5%) | 800 | 88 (11.0%) | 7 |
| 21 | Guo, T. (2020) | China | A single-centre retrospective observational cohort study | 187 | 23.0% | 58.5 (43.8–73.2) | 43 | 29 (67.4%) | 144 | 37 (86.0%) | 7 |
| 22 | Gupta, S. (2020) | USA | A multi-centre cohort study | 2215 | 35.4% | 62 (51–71) | 784 | 158 (20.2%) | 1431 | 130 (9.1%) | 7 |
| 23 | Halvatsiotis, P. (2020) | Greece | A multi-centre retrospective corss-sectional study | 86 | 28.9% | 65.5 (56–73) | 26 | 4 (15.4%) | 60 | 14 (23.3%) | 7 |
| 24 | Harmouch, F. (2020) | USA | A retrospective cohort study | 560 | 14.5% | 63 (39–87) | 81 | 19 (23.5%) | 479 | 35 (7.3%) | 5 |
| 25 | He, X. W. (2020) | China | A single-centre retrospective cohort study | 54 | 48.1% | 68.0 (59.8–74.3) | 26 | 5 (19.2) | 28 | 3 (10.7%) | 8 |
| 26 | He, Y. (2020) | China | A cohort study | 336 | 39.6% | 65 (50–77) | 133 | 36 (27.1%) | 203 | 23 (11.3%) | 6 |
| 27 | Homayounieh, F. (2020) | Iran | A retrospective cohort study | 75 | 20.0% | – | 15 | 5 (33.3%) | 60 | 13 (21.7%) | 6 |
| 28 | Hwang, J. M. (2020) | Korea | A retrospective cohort study | 103 | 25.2% | 67.6 (52.3–82.9) | 26 | 6 (23.1%) | 77 | 6 (7.8%) | 6 |
| 29 | Inciardi, R. M. (2020) | Italy | A cohort study | 99 | 26.3% | 67 (55–79) | 26 | 19 (73.1%) | 73 | 34 (46.6%) | 8 |
| 30 | Lanza, G. A. (2020) | Italy | A retrospective cohort study | 324 | 13.6% | 65.9 (50.7–81.1) | 44 | 17 (38.6%) | 280 | 50 (17.9%) | 5 |
| 31 | Li, C. (2020) | China | A retrospective cohort study | 2068 | 8.8% | 63 (51–70) | 183 | 28 (15.3%) | 1885 | 154 (8.2%) | 5 |
| 32 | Li, J. (2020) | China | A retrospective cohort study | 74 | 18.9% | 66 (55–72) | 14 | 4 (28.6%) | 60 | 2 (3.3%) | 6 |
| 33 | Lu, J. (2020) | China | A retrospective cohort study | 20 | 50.0% | 69.8 (57.8–81.8) | 10 | 2 (20.0%) | 10 | 2 (20.0%) | 6 |
| 34 | McCullough, S. A. (2020) | USA | A retrospective observational cohort study | 756 | 11.9% | 63.3 (47.3–79.3) | 90 | 16 (17.8%) | 666 | 39 (5.9%) | 5 |
| 35 | Nikpouraghdam, M. (2020) | Iran | A retrospective cohort study | 2964 | 8.1% | 55.50 (40.4–70.7) | 239 | 4 (1.7%) | 2725 | 33 (1.2%) | 6 |
| 36 | Pan, F. (2020) | China | A case-control study | 124 | 71.8% | 68 (61–75) | 89 | 13 (14.6%) | 35 | 6 (17.1%) | 5 |
| 37 | Peterson, E. (2020) | USA | A single-centre retrospective cohort study | 355 | 22.5% | – | 80 | 24 (30.0%) | 275 | 53 (19.3%) | 8 |
| 38 | Rastad, H. (2020) | Iran | A retrospective cohort study | 2957 | 10.2% | 54.8 (37.9–71.7) | 301 | 54 (17.9%) | 2656 | 260 (9.8%) | 5 |
| 39 | Rath, D. (2020) | Germany | A consecutive prospective cohort study | 123 | 13.0% | 68 (53–83) | 16 | 6 (37.5%) | 107 | 22 (20.6%) | 7 |
| 40 | Rey, J. R. (2020) | Spain | A retrospective cohort study | 3080 | 20.3% | 62.3 (42.0–82.6) | 626 | 74 (11.8%) | 2454 | 78 (3.2%) | 7 |
| 41 | Shi, S. (2020) | China | A retrospective cohort study | 671 | 9.2% | 63 (50–72) | 62 | 21 (33.9%) | 609 | 39 (6.4%) | 5 |
| 42 | Sun, J. H. (2020) | China | A retrospective cohort study | 939 | 11.7% | 62 (51–70) | 110 | 8 (7.3%) | 829 | 57 (6.9%) | 6 |
| 43 | Twigg, H. L. (2020) | USA | A cohort study | 242 | 19.8% | 59.6 (44.1–75.1) | 48 | 9 (18.8%) | 194 | 19 (9.8%) | 6 |
| 44 | Xu, J. (2020) | China | A multicenter retrospective cohort study | 239 | 61.5% | 62.5 (49.2–75.8) | 147 | 21 (14.3%) | 92 | 14 (15.2%) | 6 |
| 45 | Zhang, J. (2020) | China | A retrospective cohort study | 541 | 9.8% | – | 53 | 32 (60.4%) | 488 | 112 (23.0%) | 6 |
| 46 | Zhao, Y. (2020) | China | A single-centre retrospective case control study | 539 | 23.2% | 58 (43–69) | 125 | 20 (16.0%) | 414 | 17 (4.1%) | 6 |
| 47 | Zhou, F. (2020) | China | A multi-centre retrospective cohort study | 191 | 28.3% | 56·0 (46·0–67·0) | 54 | 13 (24.1%) | 137 | 2 (1.5%) | 5 |
#The numbers in our study were accurate to one digit after the decimal point, but some of the numbers were only displayed as integers in a few primary articles included.
¶The percentage of cases in each group was marked in the bracket.